Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Nov:58:197-9.
doi: 10.1016/j.jpsychires.2014.07.022. Epub 2014 Aug 6.

Riluzole likely lacks antidepressant efficacy in ketamine non-responders

Mark J Niciu  1 , David A Luckenbaugh  2 , Dawn F Ionescu  2 , Erica M Richards  2 , Jennifer L Vande Voort  2 , Elizabeth D Ballard  2 , Nancy E Brutsche  2 , Maura L Furey  2 , Carlos A Zarate Jr  2
Affiliations
Randomized Controlled Trial

Riluzole likely lacks antidepressant efficacy in ketamine non-responders

Mark J Niciu et al. J Psychiatr Res. 2014 Nov.
No abstract available

Keywords: Glutamate; Ketamine; Major depressive disorder; Riluzole; Treatment-resistant depression.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Drs. Niciu, Ionescu, Richards, Vande Voort, Ballard, Ms. Brutsche and Mr. Luckenbaugh have no potential financial conflicts of interest to disclose. Dr. Furey is listed as a co-inventor on a patent application for the use of scopolamine in major depression, and Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Drs. Furey and Zarate have assigned their rights in the patent to the U.S. Government but will share a percentage of any royalties that may be received by the Government.

Figures

Fig. 1
Fig. 1
Riluzole Appears to Lack Antidepressant Efficacy in Ketamine Non-Responders. On randomization to flexible dose riluzole (100–200 mg/day) or placebo 4–6 h after a single open-label subanesthetic dose (0.5 mg/kg) ketamine infusion, there was no difference in antidepressant efficacy over the ensuing four weeks in ketamine non-responders (as defined by <50% MADRS improvement from pre-randomization baseline at 230 min post-infusion) [group × time interaction: [F(27,231) = 1.15, p = .29], Abbreviations: TRD: treatment-resistant major depressive disorder.
See this image and copyright information in PMC

References

    1. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry. 2010;15:501–11. - PMC - PubMed
    1. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526–33. - PMC - PubMed
    1. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71–82. - PMC - PubMed
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. - PubMed
    1. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA, Jr, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol. 2014;54:119–39. - PMC - PubMed

Publication types